Evidence map›Paper›PMID 33231929›Full record

Trial reportPharmacology research & perspectives2020

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity.

Stacey Tannenbaum, Martin den Adel, Walter Krauwinkel, John Meijer, Adriana Hollestein-Havelaar, Frank Verheggen, Donald Newgreen

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pharmacology research & perspectives, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. The Effectiveness in Activating M-Type KInternational journal of molecular sciences · 2021
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Stacey TannenbaumAstellas Pharma Global Development Inc., Northbrook, IL, USA.
Martin den AdelAstellas Pharma Europe B.V., Leiden, The Netherlands.
Walter KrauwinkelAstellas Pharma Europe B.V., Leiden, The Netherlands.
John MeijerAstellas Pharma Europe B.V., Leiden, The Netherlands.
Adriana Hollestein-HavelaarAstellas Pharma Europe B.V., Leiden, The Netherlands.
Frank VerheggenAstellas Pharma Europe B.V., Leiden, The Netherlands.
Donald NewgreenAstellas Pharma Europe B.V., Leiden, The Netherlands.
Astellas Pharma (Netherlands) · NLAstellas Pharma (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this investigation was to characterize and compare the pharmacokinetics (PK) of the antimuscarinic drug solifenacin in pediatric patients with overactive bladder (OAB) or neurogenic detrusor overactivity (NDO) utilizing data from three phase III trials. LION was a placebo-controlled, 12-week trial in children (5-<12 years) and adolescents (12-<18 years) with OAB. MONKEY and MARMOSET were open-label, 52-week trials in children and adolescents or younger children (6 months-<5 years), respectively, with NDO. During the trials, solifenacin doses could be titrated to weight-adjusted pediatric equivalent doses (PEDs) of 2.5, 5, 7.5, or 10 mg day

Indexed as

AdolescentChildChild, PreschoolDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansInfantMaleMuscarinic AntagonistsSingle-Blind MethodSolifenacin SuccinateUrinary Bladder, OveractiveUrological AgentsMuscarinic AntagonistsSolifenacin SuccinateUrological Agentsnephrology - urologypediatrics - childrenpharmacokinetics

Identifiers

PMID33231929
PMCPMC7685239
OpenAlexW3110459415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.